Research Studies
Back to Results
A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Primary Objective
Evaluate the safety and tolerability of FOR46 at escalating dose levels and administered intravenously (IV) every 21 days in relapsed/refractory multiple myeloma patients. And determine the maximum-tolerated dose and/or the recommended Phase 2 dose (RP2D) of FOR46 administered IV every 21 days in relapsed/refractory multiple myeloma patients.
Details
Age
Adult
Type of Study
Treatment
Location
University of Colorado Hospital
Principal Investigator
Tomer Mark, MD
Study ID
Protocol Number: 18-2354
More information available at ClinicalTrials.gov: NCT03650491
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers